Edesa Historical Balance Sheet

EDSA Stock

USD 4.57 0.02 0.44%

Trend analysis of Edesa Biotech balance sheet accounts such as Total Current Liabilities of 1.3 M or Total Stockholder Equity of 6.4 M provides information on Edesa Biotech's total assets, liabilities, and equity, which is the actual value of Edesa Biotech to its prevalent stockholders. By breaking down trends over time using Edesa Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Edesa Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edesa Biotech is a good buy for the upcoming year.

Edesa Biotech Inventory

(1.07 Million)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

About Edesa Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Edesa Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Edesa Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Edesa currently owns. An asset can also be divided into two categories, current and non-current.

Edesa Biotech Balance Sheet Chart

Edesa Biotech Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Edesa Biotech uses and utilizes its capital. It also shows what exactly a company owns and owes.

At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.

Total Assets Other Current Liab Total Current Liabilities Non Current Assets Total Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Edesa Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Edesa Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Edesa Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Edesa Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Accounts Payable

An accounting item on the balance sheet that represents Edesa Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Edesa Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Edesa Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	2.1M	1.7M	2.0M	1.2M
Total Assets	11.6M	8.9M	10.2M	8.7M

Other Current Liab Total Assets

Edesa Biotech balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Net Receivables	Property Plant And Equipment Gross	Current Deferred Revenue	Non Current Liabilities Total	Intangible Assets	Common Stock Total Equity	Inventory	Common Stock	Short Term Investments	Other Assets
Total Assets		0.37	0.35	0.75	-0.8	-0.59	0.81	0.41	-0.02	0.89	0.23	0.41	0.1	0.26	0.97	0.21	0.32	0.24	-0.38	0.19	0.73	0.44	-0.14	0.6	0.45	0.14
Other Current Liab	0.37		0.99	-0.2	-0.41	-0.28	0.44	0.26	0.19	0.29	0.25	0.16	0.52	0.8	0.33	-0.29	0.13	-0.28	0.26	0.62	-0.1	-0.25	-0.2	0.02	0.05	-0.17
Total Current Liabilities	0.35	0.99		-0.21	-0.4	-0.24	0.43	0.25	0.2	0.27	0.26	0.17	0.52	0.79	0.31	-0.33	0.13	-0.32	0.26	0.6	-0.09	-0.3	-0.21	-0.02	0.09	-0.11
Total Stockholder Equity	0.75	-0.2	-0.21		-0.34	-0.57	0.36	0.44	0.07	0.58	0.28	0.47	-0.06	-0.44	0.69	0.32	0.39	0.35	-0.56	-0.48	0.86	0.56	-0.24	0.75	0.66	0.19
Net Debt	-0.8	-0.41	-0.4	-0.34		0.28	-0.99	-0.14	0.09	-0.82	-0.04	-0.28	-0.06	-0.59	-0.83	0.0	-0.14	0.0	0.21	-0.59	-0.45	-0.17	-0.02	-0.19	-0.04	-0.16
Retained Earnings	-0.59	-0.28	-0.24	-0.57	0.28		-0.32	-0.49	-0.47	-0.53	-0.47	-0.16	-0.45	0.02	-0.53	-0.36	-0.02	-0.41	0.11	0.17	-0.54	-0.57	0.32	-0.93	-0.38	0.49
Cash	0.81	0.44	0.43	0.36	-0.99	-0.32		0.21	-0.01	0.81	0.13	0.29	0.14	0.59	0.83	-0.04	0.15	-0.04	-0.17	0.57	0.47	0.15	-0.04	0.23	0.08	0.15
Non Current Assets Total	0.41	0.26	0.25	0.44	-0.14	-0.49	0.21		0.62	0.05	0.89	0.57	0.57	-0.09	0.21	-0.36	0.47	-0.33	-0.19	-0.27	0.39	-0.15	-0.81	0.45	0.64	0.17
Non Currrent Assets Other	-0.02	0.19	0.2	0.07	0.09	-0.47	-0.01	0.62		-0.19	0.88	0.37	0.78	-0.13	-0.14	-0.51	0.12	-0.48	0.15	-0.31	0.14	-0.3	-0.76	0.35	0.41	-0.26
Cash And Short Term Investments	0.89	0.29	0.27	0.58	-0.82	-0.53	0.81	0.05	-0.19		-0.07	0.11	-0.06	0.37	0.96	0.45	-0.05	0.45	-0.24	0.36	0.62	0.64	0.25	0.51	0.16	-0.05
Common Stock Shares Outstanding	0.23	0.25	0.26	0.28	-0.04	-0.47	0.13	0.89	0.88	-0.07		0.45	0.75	-0.1	0.06	-0.54	0.4	-0.5	0.06	-0.3	0.29	-0.31	-0.89	0.39	0.6	0.04
Other Current Assets	0.41	0.16	0.17	0.47	-0.28	-0.16	0.29	0.57	0.37	0.11	0.45		0.22	-0.13	0.28	-0.4	0.5	-0.38	-0.66	-0.25	0.41	-0.23	-0.6	0.16	0.59	0.34
Other Stockholder Equity	0.1	0.52	0.52	-0.06	-0.06	-0.45	0.14	0.57	0.78	-0.06	0.75	0.22		0.21	0.0	-0.47	0.16	-0.44	0.42	0.0	-0.11	-0.34	-0.63	0.25	0.13	-0.4
Total Liab	0.26	0.8	0.79	-0.44	-0.59	0.02	0.59	-0.09	-0.13	0.37	-0.1	-0.13	0.21		0.31	-0.18	-0.13	-0.19	0.31	0.96	-0.27	-0.21	0.17	-0.28	-0.35	-0.08
Total Current Assets	0.97	0.33	0.31	0.69	-0.83	-0.53	0.83	0.21	-0.14	0.96	0.06	0.28	0.0	0.31		0.31	0.22	0.33	-0.33	0.27	0.67	0.53	0.05	0.53	0.31	0.09
Property Plant And Equipment Net	0.21	-0.29	-0.33	0.32	0.0	-0.36	-0.04	-0.36	-0.51	0.45	-0.54	-0.4	-0.47	-0.18	0.31		-0.42	1.0	-0.25	-0.07	0.24	0.91	0.61	0.46	-0.13	-0.33
Net Receivables	0.32	0.13	0.13	0.39	-0.14	-0.02	0.15	0.47	0.12	-0.05	0.4	0.5	0.16	-0.13	0.22	-0.42		-0.4	-0.23	-0.22	0.13	-0.32	-0.66	0.09	0.36	0.42
Property Plant And Equipment Gross	0.24	-0.28	-0.32	0.35	0.0	-0.41	-0.04	-0.33	-0.48	0.45	-0.5	-0.38	-0.44	-0.19	0.33	1.0	-0.4		-0.26	-0.09	0.26	0.92	0.58	0.5	-0.11	-0.34
Current Deferred Revenue	-0.38	0.26	0.26	-0.56	0.21	0.11	-0.17	-0.19	0.15	-0.24	0.06	-0.66	0.42	0.31	-0.33	-0.25	-0.23	-0.26		0.27	-0.52	-0.27	0.14	-0.21	-0.47	-0.46
Non Current Liabilities Total	0.19	0.62	0.6	-0.48	-0.59	0.17	0.57	-0.27	-0.31	0.36	-0.3	-0.25	0.0	0.96	0.27	-0.07	-0.22	-0.09	0.27		-0.32	-0.15	0.35	-0.37	-0.5	-0.04
Intangible Assets	0.73	-0.1	-0.09	0.86	-0.45	-0.54	0.47	0.39	0.14	0.62	0.29	0.41	-0.11	-0.27	0.67	0.24	0.13	0.26	-0.52	-0.32		0.49	-0.15	0.66	0.71	0.29
Common Stock Total Equity	0.44	-0.25	-0.3	0.56	-0.17	-0.57	0.15	-0.15	-0.3	0.64	-0.31	-0.23	-0.34	-0.21	0.53	0.91	-0.32	0.92	-0.27	-0.15	0.49		0.46	0.67	0.02	-0.35
Inventory	-0.14	-0.2	-0.21	-0.24	-0.02	0.32	-0.04	-0.81	-0.76	0.25	-0.89	-0.6	-0.63	0.17	0.05	0.61	-0.66	0.58	0.14	0.35	-0.15	0.46		-0.25	-0.55	-0.17
Common Stock	0.6	0.02	-0.02	0.75	-0.19	-0.93	0.23	0.45	0.35	0.51	0.39	0.16	0.25	-0.28	0.53	0.46	0.09	0.5	-0.21	-0.37	0.66	0.67	-0.25		0.46	-0.4
Short Term Investments	0.45	0.05	0.09	0.66	-0.04	-0.38	0.08	0.64	0.41	0.16	0.6	0.59	0.13	-0.35	0.31	-0.13	0.36	-0.11	-0.47	-0.5	0.71	0.02	-0.55	0.46		0.42
Other Assets	0.14	-0.17	-0.11	0.19	-0.16	0.49	0.15	0.17	-0.26	-0.05	0.04	0.34	-0.4	-0.08	0.09	-0.33	0.42	-0.34	-0.46	-0.04	0.29	-0.35	-0.17	-0.4	0.42

Click cells to compare fundamentals

Edesa Biotech Account Relationship Matchups

Edesa Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Liab	1.5M	1.4M	2.1M	1.7M	2.0M	1.2M
Total Current Liabilities	1.5M	1.5M	2.1M	1.8M	2.1M	1.3M
Total Stockholder Equity	6.6M	13.1M	9.4M	7.0M	8.1M	6.4M
Net Debt	(7.0M)	(7.7M)	(7.1M)	(5.3M)	(4.7M)	(5.0M)
Retained Earnings	(13.1M)	(26.5M)	(44.0M)	(52.4M)	(47.2M)	(44.8M)
Cash	7.2M	7.8M	7.1M	5.4M	6.2M	5.6M
Non Current Assets Total	2.7M	2.5M	2.5M	2.5M	2.8M	3.0M
Cash And Short Term Investments	7.2M	7.8M	7.1M	5.4M	6.2M	6.8M
Common Stock Shares Outstanding	1.2M	1.7M	2.1M	2.9M	3.3M	3.5M
Liabilities And Stockholders Equity	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Assets	890.3K	948.6K	2.0M	448.9K	516.2K	429.9K
Other Stockholder Equity	1.3M	4.7M	11.2M	13.0M	15.0M	15.7M
Total Liab	4.1M	1.5M	2.2M	1.8M	2.1M	2.3M
Total Current Assets	8.1M	12.1M	9.1M	6.4M	7.4M	7.6M
Property Plant And Equipment Net	174.8K	111.6K	31.2K	100.1K	90.1K	85.6K
Net Receivables	87.4K	3.3M	1.3M	626.5K	720.5K	521.2K
Property Plant And Equipment Gross	174.8K	145.4K	70.7K	143.9K	129.5K	123.1K
Accumulated Other Comprehensive Income	(287.2K)	(205.3K)	(213.6K)	(214.6K)	(246.8K)	(234.5K)
Non Current Liabilities Total	2.6M	67.7K	43.7K	19.8K	17.8K	16.9K
Inventory	224.3K	(217.1K)	(87.4K)	(1.3M)	(1.1M)	(1.1M)
Common Stock	18.5M	34.9M	42.5M	46.6M	53.6M	39.4M
Property Plant Equipment	73.1K	174.8K	111.6K	31.2K	28.0K	26.6K
Accounts Payable	1.5M	1.4M	2.1M	1.7K	2.0K	1.9K
Net Tangible Assets	5.3M	4.1M	10.7M	7.1M	8.2M	4.3M
Net Invested Capital	6.6M	13.1M	9.4M	7.0M	8.1M	9.4M
Net Working Capital	6.6M	10.6M	7.0M	4.6M	4.2M	5.8M
Capital Stock	18.5M	34.9M	42.5M	46.6M	53.6M	38.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

WD	Walker Dunlop
MSFT	Microsoft
BAC	Bank of America

When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:

How To Invest In Edesa

Details

Is Edesa Stock a good investment?

Details

What is Edesa Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Edesa Stock analysis

When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.

	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(20.16)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.56)

Return On Equity

(0.96)

The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edesa Historical Balance Sheet

Edesa Biotech Inventory

(1.07 Million)

About Edesa Balance Sheet Analysis

Edesa Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Non Current Assets Total

Accounts Payable

Edesa Biotech balance sheet Correlations

Edesa Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edesa Biotech balance sheet Accounts

Also Currently Popular

Complementary Tools for Edesa Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Liabilities	+ 0.99	Other Current Liab
Total Current Assets	+ 0.97	Total Assets
Total Current Assets	+ 0.96	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.96	Total Liab
Common Stock Total Equity	+ 0.92	Property Plant And Equipment Gross

Cash	- 0.99	Net Debt
Common Stock	- 0.93	Retained Earnings
Inventory	- 0.89	Common Stock Shares Outstanding
Total Current Assets	- 0.83	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt
Inventory	- 0.81	Non Current Assets Total